Literature DB >> 28813638

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.

Anne Kuijer1, Marieke Straver1, Bianca den Dekker1, Annelotte C M van Bommel1, Sjoerd G Elias1, Carolien H Smorenburg1, Jelle Wesseling1, Sabine C Linn1, Emiel J Th Rutgers1, Sabine Siesling1, Thijs van Dalen1.   

Abstract

Purpose Gene-expression profiles increasingly are used in addition to conventional prognostic factors to guide adjuvant chemotherapy (CT) decisions. The Dutch guideline suggests use of validated gene-expression profiles in patients with estrogen receptor (ER) -positive, early-stage breast cancer without overt lymph node metastases. We aimed to assess the impact of a 70-gene signature (70-GS) test on CT decisions in patients with ER-positive, early-stage breast cancer. Patients and Methods In a prospective, observational, multicenter study in patients younger than 70 years old who had undergone surgery for ER-positive, early-stage breast cancer, physicians were asked whether they intended to administer adjuvant CT before deployment of the 70-GS test and after the test result was available. Results Between October 1, 2013, and December 31, 2015, 660 patients, treated in 33 hospitals, were enrolled. Fifty-one percent of patients had pT1cN0, BRII, HER2-Neu-negative breast cancer. On the basis of conventional clinicopathological characteristics, physicians recommended CT in 270 (41%) of the 660 patients and recommended withholding CT in 107 (16%) of the 660 patients. For the remaining 43% of patients, the physicians were unsure and unable to give advice before 70-GS testing. In patients for whom CT was initially recommended or not recommended, 56% and 59%, respectively, were assigned to a low-risk profile by the 70-GS (κ, 0.02; 95% CI, -0.08 to 0.11). After disclosure of the 70-GS test result, the preliminary advice was changed in 51% of patients who received a recommendation before testing; the definitive CT recommendation of the physician was in line with the 70-GS result in 96% of patients. Conclusion In this prospective, multicenter study in a selection of patients with ER-positive, early-stage breast cancer, 70-GS use changed the physician-intended recommendation to administer CT in half of the patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28813638     DOI: 10.1200/JCO.2016.70.3959

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

Review 1.  Advancement of prognostic models in breast cancer: a narrative review.

Authors:  Ningning Min; Yufan Wei; Yiqiong Zheng; Xiru Li
Journal:  Gland Surg       Date:  2021-09

2.  Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.

Authors:  Kelsey H Natsuhara; Katya Losk; Tari A King; Nancy U Lin; Kristen Camuso; Mehra Golshan; Stephen Pochebit; Jane E Brock; Craig A Bunnell; Rachel A Freedman
Journal:  Oncologist       Date:  2018-08-03

3.  The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.

Authors:  Stephane Thibodeau; Ioannis A Voutsadakis
Journal:  Eur J Breast Health       Date:  2019-07-01

4.  A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy.

Authors:  Pu Cheng; Zhen Wang; Guoming Hu; Qi Huang; Mengjiao Han; Jian Huang
Journal:  Oncotarget       Date:  2017-10-17

5.  Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.

Authors:  Jing Yu; Jiayi Wu; Ou Huang; Jianrong He; Li Zhu; Weiguo Chen; Yafen Li; Xiaosong Chen; Kunwei Shen
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

6.  Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?

Authors:  Jing Yu; Jiayi Wu; Ou Huang; Jianrong He; Zhu Li; Weiguo Chen; Yafen Li; Xiaosong Chen; Kunwei Shen
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

7.  MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature.

Authors:  Deena M A Gendoo; Michael Zon; Vandana Sandhu; Venkata S K Manem; Natchar Ratanasirigulchai; Gregory M Chen; Levi Waldron; Benjamin Haibe-Kains
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

8.  A prognostic 10-lncRNA expression signature for predicting the risk of tumour recurrence in breast cancer patients.

Authors:  Jianing Tang; Jiangbo Ren; Qiuxia Cui; Dan Zhang; Deguang Kong; Xing Liao; Mengxin Lu; Yan Gong; Gaosong Wu
Journal:  J Cell Mol Med       Date:  2019-08-20       Impact factor: 5.310

9.  Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2020-03-06

10.  Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study.

Authors:  Julia E C van Steenhoven; Anne Kuijer; Paul J van Diest; Joost M van Gorp; Marieke Straver; Sjoerd G Elias; Jelle Wesseling; Emiel Rutgers; Johanna N H Timmer-Bonte; Peter Nieboer; Tineke J Smilde; Alex Imholz; Charlotte F J M Blanken; Sabine Siesling; Thijs van Dalen
Journal:  Genes (Basel)       Date:  2018-05-17       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.